Under the Patronage of His Royal Highness the Crown Prince Governor of Riyadh Region Inaugurates MOMENTUM 2025 Development Finance Conference

Under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince, Prime Minister, and Chairman of the Board of Directors of the National Development Fund (NDF), His Royal Highness Prince Faisal bin Bandar bin Abdulaziz, Governor of the Riyadh Region, inaugurated today MOMENTUM 2025, hosted by the NDF under […]

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial. Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today that its New Drug Application (NDA) for denifanstat (ASC40), a first-in-class, once-daily oral small molecule

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial. Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today that its New Drug Application (NDA) for denifanstat (ASC40), a first-in-class, once-daily oral small molecule

Aerolase Earns Dual Honors in MedEsthetics 2025 Readers’ Choice Awards

Neo Elite® Takes Top Honor for Acne Treatment; Era Elite® Recognized as Finalist/Runner-Up for Skin Resurfacing Excellence Aerolase Corporation, a leader in advanced laser and light-based dermatology and aesthetics solutions, today announced that its Neo Elite® has just been named winner of the Best Acne Laser Award in the MedEsthetics 2025 Readers' Choice Awards. Additionally,

Slovenian Tourist Board published an article exploring the highlights in Slovenia 2026

LJUBLJANA, Slovenia, Dec. 10, 2025 (GLOBE NEWSWIRE) — In 2026, Slovenia invites travelers – and storytellers – to explore a year rich in cultural milestones, outdoor adventures and experiences that redefine slow, meaningful travel. With the Slovenian Tourist Board at the helm, the country showcases everything from a centuries-old passion play to world-class architecture, from

Slovenian Tourist Board published an article exploring the highlights in Slovenia 2026

Slovenian Tourist Board published an article exploring the highlights in Slovenia 2026 GlobeNewswire December 10, 2025 LJUBLJANA, Slovenia, Dec. 10, 2025 (GLOBE NEWSWIRE) — In 2026, Slovenia invites travelers – and storytellers – to explore a year rich in cultural milestones, outdoor adventures and experiences that redefine slow, meaningful travel. With the Slovenian Tourist Board

Rakovina Therapeutics Announces Upcoming Webinar with Variational AI

(TSX-V:RKV),(Boerse Frankfurt – Freiverkehr:7JO0), VANCOUVER, British Columbia, Dec. 10, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that the Company will host a 60-minute webinar on December 17, 2025 at 10:00

Igyxos Biotherapeutics Announces Positive Results from Phase 1 Trial of IGX12, its First-in-Class Monoclonal Antibody for the Treatment of Male and Female Infertility

TOURS, France, Dec. 10, 2025 (GLOBE NEWSWIRE) — Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, today announced the successful completion of its Phase 1 clinical trial evaluation of IGX12. The recent Multiple Ascending Dose (MAD) Phase 1 trial of IGX12 was a randomised, placebo-controlled study in 14 healthy

CathVision Announces Appointment of Eric Thepaut as Independent Chairman of the Board and Releases ECGenius® System Version 3.5

CathVision, a medical technology company dedicated to improving clinical outcomes in cardiac electrophysiology through high-fidelity signal acquisition and intelligent software, today announced two major milestones: the appointment of Eric Thepaut as independent Chairman of the Board, and the commercial release of Version 3.5 of the ECGenius® System. https://mma.prnewswire.com/media/2842487/Eric_Thepaut.jpg Eric Thepaut Appointed Independent Chairman of the

Scroll to Top